290 EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR

289 DISCREPANCIES BETWEEN DEFINITIONS OF NULL RESPONSE TO TREATMENT WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN: IMPLICATIONS FOR NEW HCV DRUG DEVELOPMENT G. Picchio, D. Luo, S. George, A. Kwong, T. Kieffer, J. Mc Hutchison, J.-M. Pawlotsky. Tibotec, Inc, Yardley, PA, Vertex Pharmaceuticals Incorporated, Cambridge, MA, Duke University Medical Center, Durham, NC, USA; Hopital Henri Mondor, Creteil, France E-mail: gpicchio@its.jnj.com